India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
GSK's drug is 60 percent more effective in curing cancer in women World-renowned pharmaceutical company GSK has announced that the initial results of its new drug ' Mosertatag Rezedacan ', which is used to treat uterine and ovarian cancer , are encouraging. In the first phase of clinical trials, 'Mosertatag Rezedacan' has shown success in platinum-resistant ovarian cancer by 62 percent and in uterine cancer by 67 percent. GSK is preparing to start five large 'Phase-3' clinical trials in 2026 and the drug could change the way cancer is treated, said Hesham Abdullah. World-renowned pharmaceutical company GSK has announced that the initial results of its new drug used to treat uterine and ovarian cancer are very encouraging. The new antibody-drug conjugate (ADC) drug , called mosertatag rezedecan, has shown positive results in a phase 1 clinical trial. The BEHOLD-1 study , presented at the Society of Gynecologic Oncology (SGO) annual meeting in Puerto Rico, ...